Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs

Detalhes bibliográficos
Autor(a) principal: Araújo, Aurigena Antunes de
Data de Publicação: 2014
Outros Autores: Dantas, Diego de Araújo, Nascimento, Gemma Galgani do, Ribeiro, Susana Barbosa, Chaves, Katarina Melo, Silva, Vanessa de Lima, Araújo Jr., Raimundo Fernandes de, Souza, Dyego Leandro Bezerra de, Medeiros, Caroline Addison Carvalho Xavier de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRN
Texto Completo: https://repositorio.ufrn.br/jspui/handle/123456789/25424
http://dx.doi.org/10.1007/s11126-014-9290-x
Resumo: This cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ 2 test and Student’s t test, with a significance level of 5 %. Average monthly household incomes in the medication groups were 1.1–2.1 minimum wages ($339–$678). UKU Scale scores showed significant differences in side effects, mainly, clozapine, quetiapine and ziprasidone (p < 0.05). EQ-5D scores showed that all drugs except olanzapine significantly impacted mobility (p < 0.05), and proportions of individuals reporting problems in other dimensions were high: 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression. Psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent in users of atypical antipsychotic drugs, especially clozapine and ziprasidone. Olanzapine had the least side effects. QoL was impacted by side effects and economic conditions in all groups. Thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations.
id UFRN_46c183dcfd3e5c3f47085212bad150f5
oai_identifier_str oai:https://repositorio.ufrn.br:123456789/25424
network_acronym_str UFRN
network_name_str Repositório Institucional da UFRN
repository_id_str
spelling Araújo, Aurigena Antunes deDantas, Diego de AraújoNascimento, Gemma Galgani doRibeiro, Susana BarbosaChaves, Katarina MeloSilva, Vanessa de LimaAraújo Jr., Raimundo Fernandes deSouza, Dyego Leandro Bezerra deMedeiros, Caroline Addison Carvalho Xavier de2018-06-16T12:05:33Z2018-06-16T12:05:33Z2014-05-01ARAÚJO, Aurigena Antunes de et al. Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs. Psychiatric Quarterly, p. 357-67, 2014. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-014-9290-x>. Acesso em: 19 mar. 2018.1573-6709https://repositorio.ufrn.br/jspui/handle/123456789/25424http://dx.doi.org/10.1007/s11126-014-9290-xengSpringer ScienceSchizophreniaAtypical antipsychoticQuality of lifeQuality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleThis cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ 2 test and Student’s t test, with a significance level of 5 %. Average monthly household incomes in the medication groups were 1.1–2.1 minimum wages ($339–$678). UKU Scale scores showed significant differences in side effects, mainly, clozapine, quetiapine and ziprasidone (p < 0.05). EQ-5D scores showed that all drugs except olanzapine significantly impacted mobility (p < 0.05), and proportions of individuals reporting problems in other dimensions were high: 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression. Psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent in users of atypical antipsychotic drugs, especially clozapine and ziprasidone. Olanzapine had the least side effects. QoL was impacted by side effects and economic conditions in all groups. Thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNTEXTQuality of Life in Patients with Schizophrenia_2014.pdf.txtQuality of Life in Patients with Schizophrenia_2014.pdf.txtExtracted texttext/plain29956https://repositorio.ufrn.br/bitstream/123456789/25424/3/Quality%20of%20Life%20in%20Patients%20with%20Schizophrenia_2014.pdf.txt24e28512af25bf0421bb47bed8fc851eMD53THUMBNAILQuality of Life in Patients with Schizophrenia_2014.pdf.jpgQuality of Life in Patients with Schizophrenia_2014.pdf.jpgIM Thumbnailimage/jpeg5874https://repositorio.ufrn.br/bitstream/123456789/25424/4/Quality%20of%20Life%20in%20Patients%20with%20Schizophrenia_2014.pdf.jpg73e793f99b0b3bdce73901f4133820c3MD54ORIGINALQualityLifePatients_Araujo_2014.pdfQualityLifePatients_Araujo_2014.pdfapplication/pdf322917https://repositorio.ufrn.br/bitstream/123456789/25424/1/QualityLifePatients_Araujo_2014.pdf4156f54b8b8c9286671f19d8c6341e1cMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.ufrn.br/bitstream/123456789/25424/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52123456789/254242021-11-11 16:28:29.793oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2021-11-11T19:28:29Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false
dc.title.pt_BR.fl_str_mv Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
title Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
spellingShingle Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
Araújo, Aurigena Antunes de
Schizophrenia
Atypical antipsychotic
Quality of life
title_short Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
title_full Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
title_fullStr Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
title_full_unstemmed Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
title_sort Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
author Araújo, Aurigena Antunes de
author_facet Araújo, Aurigena Antunes de
Dantas, Diego de Araújo
Nascimento, Gemma Galgani do
Ribeiro, Susana Barbosa
Chaves, Katarina Melo
Silva, Vanessa de Lima
Araújo Jr., Raimundo Fernandes de
Souza, Dyego Leandro Bezerra de
Medeiros, Caroline Addison Carvalho Xavier de
author_role author
author2 Dantas, Diego de Araújo
Nascimento, Gemma Galgani do
Ribeiro, Susana Barbosa
Chaves, Katarina Melo
Silva, Vanessa de Lima
Araújo Jr., Raimundo Fernandes de
Souza, Dyego Leandro Bezerra de
Medeiros, Caroline Addison Carvalho Xavier de
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Araújo, Aurigena Antunes de
Dantas, Diego de Araújo
Nascimento, Gemma Galgani do
Ribeiro, Susana Barbosa
Chaves, Katarina Melo
Silva, Vanessa de Lima
Araújo Jr., Raimundo Fernandes de
Souza, Dyego Leandro Bezerra de
Medeiros, Caroline Addison Carvalho Xavier de
dc.subject.por.fl_str_mv Schizophrenia
Atypical antipsychotic
Quality of life
topic Schizophrenia
Atypical antipsychotic
Quality of life
description This cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ 2 test and Student’s t test, with a significance level of 5 %. Average monthly household incomes in the medication groups were 1.1–2.1 minimum wages ($339–$678). UKU Scale scores showed significant differences in side effects, mainly, clozapine, quetiapine and ziprasidone (p < 0.05). EQ-5D scores showed that all drugs except olanzapine significantly impacted mobility (p < 0.05), and proportions of individuals reporting problems in other dimensions were high: 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression. Psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent in users of atypical antipsychotic drugs, especially clozapine and ziprasidone. Olanzapine had the least side effects. QoL was impacted by side effects and economic conditions in all groups. Thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations.
publishDate 2014
dc.date.issued.fl_str_mv 2014-05-01
dc.date.accessioned.fl_str_mv 2018-06-16T12:05:33Z
dc.date.available.fl_str_mv 2018-06-16T12:05:33Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ARAÚJO, Aurigena Antunes de et al. Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs. Psychiatric Quarterly, p. 357-67, 2014. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-014-9290-x>. Acesso em: 19 mar. 2018.
dc.identifier.uri.fl_str_mv https://repositorio.ufrn.br/jspui/handle/123456789/25424
dc.identifier.issn.none.fl_str_mv 1573-6709
dc.identifier.doi.none.fl_str_mv http://dx.doi.org/10.1007/s11126-014-9290-x
identifier_str_mv ARAÚJO, Aurigena Antunes de et al. Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs. Psychiatric Quarterly, p. 357-67, 2014. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-014-9290-x>. Acesso em: 19 mar. 2018.
1573-6709
url https://repositorio.ufrn.br/jspui/handle/123456789/25424
http://dx.doi.org/10.1007/s11126-014-9290-x
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer Science
publisher.none.fl_str_mv Springer Science
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRN
instname:Universidade Federal do Rio Grande do Norte (UFRN)
instacron:UFRN
instname_str Universidade Federal do Rio Grande do Norte (UFRN)
instacron_str UFRN
institution UFRN
reponame_str Repositório Institucional da UFRN
collection Repositório Institucional da UFRN
bitstream.url.fl_str_mv https://repositorio.ufrn.br/bitstream/123456789/25424/3/Quality%20of%20Life%20in%20Patients%20with%20Schizophrenia_2014.pdf.txt
https://repositorio.ufrn.br/bitstream/123456789/25424/4/Quality%20of%20Life%20in%20Patients%20with%20Schizophrenia_2014.pdf.jpg
https://repositorio.ufrn.br/bitstream/123456789/25424/1/QualityLifePatients_Araujo_2014.pdf
https://repositorio.ufrn.br/bitstream/123456789/25424/2/license.txt
bitstream.checksum.fl_str_mv 24e28512af25bf0421bb47bed8fc851e
73e793f99b0b3bdce73901f4133820c3
4156f54b8b8c9286671f19d8c6341e1c
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)
repository.mail.fl_str_mv
_version_ 1802117885900881920